| T细胞免疫治疗实体肿瘤的临床试验疗效分析 |
| |
| 引用本文： | 母松,李子林,金艾顺. T细胞免疫治疗实体肿瘤的临床试验疗效分析[J]. 国际免疫学杂志, 2021, 44(1): 51-58 |
| |
| 作者姓名： | 母松 李子林 金艾顺 |
| |
| 作者单位： | 重庆医科大学基础医学院免疫学教研室 400016;重庆医科大学基础医学院肿瘤免疫基础与转化研究重庆市重点实验室 400016 |
| |
| 基金项目： | 国家自然科学基金(81872329)。 |
| |
| 摘 要： | 过继性T细胞治疗(adoptive cell transfer therapy，ACT)是以肿瘤浸润淋巴细胞(tumor infiltrating lymphocyte，TIL)、基因工程编辑的T细胞受体T细胞(T cell receptor engineered T cells，TCR-T)和嵌合抗原受体T细胞(ch...
|
| 关 键 词： | T细胞免疫疗法 实体肿瘤 临床疗效 不良反应 |
Clinical trial analysis of T cell immunotherapy for solid tumor |
| |
| Mu Song,Li Zilin,Jin Aishun. Clinical trial analysis of T cell immunotherapy for solid tumor[J]. International Journal of Immunology, 2021, 44(1): 51-58 |
| |
| Authors: | Mu Song Li Zilin Jin Aishun |
| |
| Affiliation: | (Department of Immunology,School of Basic Medical Sciences,Chongqing Medical University,Chongqing 400016,China;Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology,School of Basic Medical Sciences,Chongqing Medical University,Chongqing 400016,China) |
| |
| Abstract: | Adoptive T cell therapy(ACT)is a specific cellular immunotherapy based on tumor infiltrating lymphocytes(TIL),genetically engineered T cell receptor T cells(TCR-T)and chimeric antigen receptor T cells(CAR-T).In recent years,TIL and TCR-T immunotherapy,especially TIL and TCR-T combined with other regimens such as interleukin(IL)-2,programmed death-1(PD-1)antibody and radiotherapy,have achieved remarkable progress in several cases of clinical trials in patients with advanced solid tumors,but the related studies are still in the stage of preclinical research.Here we review the efficacy and common adverse reactions of TIL and TCR-T cell therapy in clinical trials in the treatment of solid tumors. |
| |
| Keywords: | T cell immunotherapy Solid tumor Clinical efficacy Adverse reactions |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
